Colesevelam as an Add-On Treatment for Control of Dyslipidemia and Hyperglycemia in Type 2 Diabetes

Canadian Journal of Diabetes

Volumn 40, Issue 2, 2016, Pages 112-114

  Sandhu, Supna ^a   Moosavi, Mandana ^a   Golmohammadi, Kamran ^a   Francis, Gordon A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLESEVELAM; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HYPOCHOLESTEROLEMIC AGENT;

ADD ON THERAPY; ANTIDIABETIC ACTIVITY; ARTICLE; CONSTIPATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS;

ANTICHOLESTEREMIC AGENTS; COLESEVELAM HYDROCHLORIDE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA;

EID: 84949034519     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2015.07.008     Document Type: Article

References (27)

1. Bays H., Dujovne C. Colesevelam HCl: A non-systemic lipid-altering drug. Expert Opin Pharmacother 2003, 4:779-790.
2. Garg A., Grundy S.M. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: A short-term, double-blind, crossover trial. Ann Intern Med 1994, 121:416-422.
3. Brietzke S.A. Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin North Am 2015, 99:87-106.
4. Mancini G.B., Hegele R.A., Leiter L.A. Dyslipidemia. Can J Diabetes 2013, 37(Suppl 1):S110-16.
5. American Diabetes Association Seven approaches to glycemic treatment. Diabetes Care 2015, 38(Suppl.):S41-8.
6. Zieve F.J., Kalin M.F., Schwartz S.L., Jones M.R., Bailey W.L. Results of the glucose-lowering effect of welchol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007, 29:74-83.
7. Goldberg R.B., Fonseca V.A., Truitt K.E., Jones M.R. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008, 168:1531-1540.
8. Fonseca V.A., Rosenstock J., Wang A.C., Truitt K.E., Jones M.R. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008, 31:1479-1484.
9. Bays H.E., Goldberg R.B., Truitt K.E., Jones M.R. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: Glucose and lipid effects. Arch Intern Med 2008, 168:1975-1983.
10. Schwartz S.L., Lai Y.L., Xu J., Abby S.L., Misir S., Jones M.R., et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: A pilot study. Metab Syndr Relat Disord 2010, 8:179-188.
11. Rosenstock J., Fonseca V.A., Garvey W.T., Goldberg R.B., Handelsman Y., Abby S.L., et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract 2010, 16:629-640.
12. Ooi C.P., Loke S.C. Colesevelam for type 2 diabetes mellitus: An abridged Cochrane review. Diabet Med 2014, 31:2-14.
13. Crouse J.R. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987, 83:243-248.
14. Brown K.S., Armstrong I.C., Wang A., et al. Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. J Cin Pharmacol 2010, 50:554-565.
15. Beysen C., Murphy E.J., Deines K., Chan M., Tsang E., Glass A., et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: A randomised controlled study. Diabetologia 2012, 55:432-442.
16. Harach T., Pols T.W., Nomura M., Maida A., Watanabe M., Auwerx J., et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2012, 2:430.
17. Potthoff M.J., Potts A., He T., Duarte J.A., Taussig R., Mangelsdorf D.J., et al. Colesevelam suppresses hepatic glycogenolysis by tgr5-mediated induction of glp-1 action in dio mice. Am J Physiol Gastrointest Liver Physiol 2013, 304:G371-80.
18. Suzuki T., Oba K., Igari Y., Matsumura N., Watanabe K., Futami-Suda S., et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like peptide-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007, 74:338-343.
19. Marina A.L., Utzschneider K.M., Wright L.A., Montgomery B.K., Marcovina S.M., Kahn S.E. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and beta-cell function. Diabetes Care 2012, 35:1119-1125.
20. Koide M., Okabayashi Y., Otsuki M. Role of endogenous bile on basal and postprandial cck release in humans. Digest Dis Sci 1993, 38:1284-1290.
21. Koop I., Schindler M., Bosshammer A., Scheibner J., Stange E., Koop H. Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids. Gut 1996, 39:661-667.
22. Hofmann A.F., Mangelsdorf D.J., Kliewer S.A. Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: A new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol 2009, 7:1151-1154.
23. Cheung G.W., Kokorovic A., Lam C.K., Chari M., Lam T.K. Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab 2009, 10:99-109.
24. Program L.R.C. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351-364.
25. Bays H.E., Davidson M., Jones M.R., Abby S.L. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity c-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006, 97:1198-1205.
26. Gavin J.R., Jones M.R., Ford D.M., Truitt K.E. Safety and efficacy of colesevelam HCl in the treatment of elderly patients. Drugs Aging 2014, 31:461-470.
27. Stein E.A., Marais A.D., Szamosi T., Rall F.J., Schurr D., Urbina E.M., et al. Colesevelam hydrochloride: Efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr 2010, 156:231-236.